Anaptysbio, Inc 8-K, filed Mar 9, 2020
Anaptysbio, Inc (ANAB)
8-K
2020-03-09
For: 2020-03-06
View Original
Added on
April 04, 2026
About this 8-K
Anaptysbio, Inc filed this 8-K on March 9, 2020, reporting on events of March 6, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: March 6, 2020
(Date of earliest event reported)
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
(858 ) 362-6295
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. | Departure of Directors or Certain Officers; Election Of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On March 6, 2020, AnaptysBio, Inc. (“AnaptysBio”) mutually agreed with Marco Londei, the Chief Medical Officer of AnaptysBio, to end his employment effective March 25, 2020. AnaptysBio has initiated recruitment of a new Chief Medical Officer to lead development of AnaptysBio’s clinical product pipeline. In the interim, J. Anthony Ware, MD, who joined the Board of Directors of AnaptysBio in August 2017, and previously served as Senior Vice President of Product Development at Eli Lilly and Company, will be providing additional oversight to AnaptysBio’s clinical and regulatory functions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AnaptysBio, Inc. | |||
Date: March 9, 2020 | By: | /s/ Hamza Suria | |
Name: Hamza Suria | |||
Title: Chief Executive Officer | |||